Quarter Comparison
Revenue
Operating Income
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 d161230dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6
EX-99.1 2 d161230dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥ 12 months post-TSHA-102, with consistent responses across ages and disease severity Advanced TSHA-102 commercial readiness activities, including market access planning initiatives and expansion of strategic partnership with C...
Source
Exhibit EX-99.1
0001193125-26-344594
Filed August 11, 2026 at 8:05 PM UTC. The figures above are from the audited statements, not from this release.